Bassil Dahiyat, Xencor CEO
June 13, 2024 10:58 AM EDT
Deals
R&D

J&J re­turns bis­pe­cif­ic T cell en­gager to Xen­cor, re­duc­ing scope of part­ner­ship

Ayisha Sharma

News Reporter

John­son & John­son is hand­ing back a bis­pe­cif­ic T cell en­gager pro­gram to its part­ner Xen­cor, end­ing a sig­nif­i­cant piece of an agree­ment be­tween the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Benev­o­len­tAI CEO is out af­ter less than a year on the job

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times